1.66
0.08 (5.06%)
| Penutupan Terdahulu | 1.58 |
| Buka | 1.58 |
| Jumlah Dagangan | 3,874,533 |
| Purata Dagangan (3B) | 7,773,365 |
| Modal Pasaran | 501,166,304 |
| Harga / Jualan (P/S) | 3.04 |
| Harga / Buku (P/B) | 91.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Operasi (TTM) | -1,164.47% |
| EPS Cair (TTM) | -2.74 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -4.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 766.18% |
| Nisbah Semasa (MRQ) | 6.68 |
| Aliran Tunai Operasi (OCF TTM) | -174.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 69.19 M |
| Pulangan Atas Aset (ROA TTM) | -31.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -177.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | Pacific Biosciences of Californ | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.90 |
|
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.06% |
| % Dimiliki oleh Institusi | 65.90% |
| Julat 52 Minggu | ||
| Median | 1.50 (-9.64%) | |
| Jumlah | 1 Jual | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 06 Mar 2026 | 1.50 (-9.64%) | Jual | 1.54 |
| 15 Dec 2025 | 2.00 (20.48%) | Pegang | 2.12 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | PacBio Completes Sale of Short-Read Sequencing Assets |
| 27 Jan 2026 | Pengumuman | PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 |
| 12 Jan 2026 | Pengumuman | PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases |
| 12 Jan 2026 | Pengumuman | PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC) |
| 12 Jan 2026 | Pengumuman | PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue |
| 08 Jan 2026 | Pengumuman | PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell |
| 30 Dec 2025 | Pengumuman | PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |